Literature DB >> 656283

Enhanced elimination of warfarin during treatment with cholestyramine.

E Jähnchen, T Meinertz, H J Gilfrich, F Kersting, U Groth.   

Abstract

1 The elimination and anticoagulant activity of a single intravenous dose of warfarin (1.0-1.2 mg/kg) without and with concomitant cholestyramine treatment (about 4 g three times daily) was studied in five healthy male subjects. 2 Cholestyramine treatment decreased the biological half-life of plasma warfarin (from a mean value of 2 days -1.3 days) and increased the total clearance of this drug (from a mean value of 37 ml kg-1 day-1--53 ml kg--1 day--1). 3 The total anticoagulant effect per dose of warfarin, as measured by the area under the effect v time curve, was also reduced by cholestyramine (average reduction of about 25%). 4 Warfarin possibly undergoes enterohepatic recycling in man which can be interrupted by cholestyramine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656283      PMCID: PMC1429341          DOI: 10.1111/j.1365-2125.1978.tb01651.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Treatment of phenprocoumon intoxication with cholestyramine.

Authors:  T Meinertz; M J Gilfrich; R Bork; E Jahnchen
Journal:  Br Med J       Date:  1977-08-13

2.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

3.  14 C-warfarin excretion in the rat.

Authors:  R Losito; M A Rousseau
Journal:  Thromb Diath Haemorrh       Date:  1972-04-30

Review 4.  Drug interactions with coumarin anticoagulants. 2.

Authors:  J K Weser; E Sellers
Journal:  N Engl J Med       Date:  1971-09-02       Impact factor: 91.245

Review 5.  Some aspects of the pharmacology of oral anticoagulants.

Authors:  W W Coon; P W Willis
Journal:  Clin Pharmacol Ther       Date:  1970 May-Jun       Impact factor: 6.875

6.  Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols.

Authors:  R J Lewis; W F Trager; A J Robinson; K K Chan
Journal:  J Lab Clin Med       Date:  1973-06

7.  The effect of novibiocin and tolbutamide on the excretion of warfarin in the bile of rats.

Authors:  W D Wosilait; L L Eisenbrandt
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-01

8.  Interaction of warfarin and nonsystemic gastrointestinal drugs.

Authors:  D S Robinson; D M Benjamin; J J McCormack
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

9.  Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.

Authors:  T Meinertz; H J Gilfrich; U Groth; H G Jonen; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

10.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

Authors:  R J Lewis; W F Trager; K K Chan; A Breckenridge; M Orme; M Roland; W Schary
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

View more
  14 in total

1.  The effect of cholestyramine and activated charcoal on glipizide absorption.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 2.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

3.  Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.

Authors:  P J Neuvonen; K Kivistö; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

4.  Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis.

Authors:  Edith A Nutescu; Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

5.  Oral cholestyramine increases elimination of warfarin after overdose.

Authors:  S Renowden; D Westmoreland; J P White; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-24

Review 6.  Drug interactions with warfarin.

Authors:  M J Serlin; A M Breckenridge
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 7.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

Review 8.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics of oral anticoagulants.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

Review 10.  Clinically important drug interactions with anticoagulants. An update.

Authors:  S Harder; P Thürmann
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.